| Literature DB >> 28670517 |
Mousa Taghipour1, Aydine Omidvar1, Mahboobeh Razmkhah2, Abbas Ghaderi2, Zahra Mojtahedi2.
Abstract
OBJECTIVE: Gliomas are the most common primary brain tumors, and have been ranked as the fourth leading cause of cancer death. Tumor mesenchymal-like stem cells (tMSCs) contribute to the aggressive behavior of glial tumors by providing a favorable microenvironment for the malignant cells. The aim of our study was to identify differential proteome of tMSCs derived from low vs. high grade glioma tumors.Entities:
Keywords: Glioma; Mesenchymal Stem Cells; Proteomics; Pyruvate Kinase
Year: 2017 PMID: 28670517 PMCID: PMC5412783 DOI: 10.22074/cellj.2016.4179
Source DB: PubMed Journal: Cell J ISSN: 2228-5806 Impact factor: 2.479
Fig.1Microscopic views of mesenchymal-like stem cells derived from A. Low and B. High grade gliomas.
Demographic information, symptoms, signs, location of tumors and pathologic diagnosis in each patient
| Case | Age (Y) | Sex | Location of symptoms | Signs | Pathologic diagnosis |
|---|---|---|---|---|---|
| 1 | 61 | F | Lt temporal | HARecent memory lossSensory dysphasia | GBM (grade IV) |
| 2 | 27 | F | Lt temporoparietal | HABlurred vision Partial seizurePapilledema | Astrocytoma (grade II) |
| 3 | 67 | M | Rt frontal | Lt side hemiparesisGTCSPapilledema | GBM (grade IV) |
| 4 | 29 | M | Rt frontal | HALt side hemiparesisGTCS | Oligoastrocytoma (grade II) |
| 5 | 33 | F | Lt frontal | HABlurred visionPapilledema | GBM (grade IV) |
| 6 | 27 | F | Lt frontal | HABlurred visionPapilledema | Astrocytoma (grade II) |
| 7 | 36 | M | Lt frontal | GTCSPapilledema | GBM (grade IV) |
| 8 | 38 | M | Rt frontotemporal | Complex partial seizureGTCS | Astrocytoma (grade II) |
| 9 | 63 | M | Lt frontal | HAGTCS | Anaplastic oligodendroglioma (grade III) |
HA; Headache, F; Female, Lt; Left, M; Male, Rt; Right, and GBM; Gliobastoma multiforme, GTCS; Generalized tonic-clonic seizures.
Mass spectrometry identification of protein spots extracted from gels of low grade (spot numbers 1-9) versus high grade tumors (spot numbers: 10-21). Spot numbers are similar the same as in Figure 1
| Spot no. | Protein name | Molecular wight (theor) | pI (theor) | Scorea | Matched peptides | Accession no. | Sequence-coverage (%) | ||
|---|---|---|---|---|---|---|---|---|---|
| 1 | Transgelin | 22.6 | 8.87 | 180 | 4 | Q01995 | 16 | ||
| 2 | Mitochondrial manganese-containing superoxide dismutase (Mn-SOD) | 24.8 | 8.35 | 131 | 2 | P04179 | 13 | ||
| 3 | GTP-binding nuclear protein Ran | 24.5 | 7.01 | 73 | 2 | P62826 | 8 | ||
| 4 | Vimentin | 53.6 | 5.06 | 193 | 3 | P08670 | 8 | ||
| 5 | 40S ribosomal Protein SA | 32.9 | 4.79 | 212 | 4 | P08865 | 16 | ||
| 6 | Vimentin | 53.6 | 5.06 | 49 | 1 | P08670 | 3 | ||
| 7 | Vimentin | 53.6 | 5.06 | 321 | 5 | P08670 | 15 | ||
| 8 | Vimentin | 53.6 | 5.06 | 128 | 2 | P08670 | 5 | ||
| 9 | Vimentin | 53.6 | 5.06 | 508 | 8 | P08670 | 21 | ||
| 10 | Superoxide dismutase, mitochondrial and a single peptide match to Peroxiredoxin-1 | 22.3 | 8.27 | 35 | 1 | Q06830 | 5 | ||
| 11 | Transgelin | 22.6 | 8.87 | 299 | 5 | Q01995 | 28 | ||
| 12 | Transgelin | 22.6 | 8.87 | 231 | 4 | Q01995 | 18 | ||
| 13 | Cathepsin B | 38.7 | 5.88 | 318 | 3 | P07858 | 12 | ||
| 14 | Cathepsin B | 38.7 | 5.88 | 442 | 4 | P07858 | 17 | ||
| 15 | Ezrin | 69.4 | 5.94 | 37 | 1 | P15311 | 1 | ||
| 16 | Pyruvate kinase (PK) | 58.4 | 7.96 | 167 | 4 | P14618 | 8 | ||
| 17 | Endoplasmin | 92.6 | 4.76 | 497 | 9 | P14625 | 10 | ||
| 18 | Vimentin | 53.6 | 5.06 | 628 | 9 | P08670 | 22 | ||
| 19 | Splicing factor, proline- and glutamine-rich | 76.2 | 9.45 | 39 | 1 | P23246 | 1 | ||
| 20 | Vimentin | 53.6 | 5.06 | 202 | 3 | P08670 | 8 | ||
| 21 | Vimentin | 53.6 | 5.06 | 156 | 3 | P08670 | 7 | ||
a; Scores greater than 35 are significant and pI; Isoelectric point.